Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Matthew Fury, MD,PhD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope National Medical Center
Duarte, California, United States
- H. Lee Moffit Cancer Center and Research Institute
Tampa, Florida, United States
- Northshore University Health System
Evanston, Illinois, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Memorial Sloan-Kettering Cancer Center at Basking Ridge
Basking Ridge, New Jersey, United States
- Memorial Sloan-Kettering Cancer Center at Commack
Commack, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Memorial Sloan-Kettering at Mercy Medical Center
Rockville Centre, New York, United States
- Memoral Sloan Kettering Cancer Center@phelps
Sleepy Hollow, New York, United States
- Abramson Cancer Center University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Fox Chase Virtua Health Cancer Program
Philadelphia, Pennsylvania, United States
- Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
- University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- University of Tennessee Cancer Institute
Memphis, Tennessee, United States
- Huntsman Cancer Institue
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2007
- Primary completion
- 31 Aug 2012
- Completion
- 31 Aug 2012
- Last update posted
- 11 Jan 2018
- Registered enrollment
- 61
- Registry id
- NCT00661427
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.